Comprehensive Cancer Center at Wake Forest University joins national breast cancer study

November 30, 1999

WINSTON-SALEM, N.C. - The Comprehensive Cancer Center at Wake Forest University has been approved to participate in a sentinel node biopsy clinical trial sponsored by the National Cancer Institute's National Surgical Adjuvant Breast and Bowel Project (NSABP).

Wake Forest is the fourth site in the Southeast and one of 20 in the country currently participating in the trial. The study will compare the effects of removing the sentinel node or nodes to the standard practice of removing a much larger number of underarm lymph nodes, known as axillary dissection.

The sentinel node is the first lymph node to which cancer is likely to spread. Sentinel node biopsy is being evaluated by a growing number of specially trained surgeons as a technique to determine if cancer has spread beyond the breast.

Edward A. Levine, M.D., the lead investigator of the study here said, "Research suggests that the sentinel node can be used to determine whether cancer has spread to other lymph nodes, but we still don't know what the impact of removing only the sentinel node will have on cancer control and survival. This trial should help fill in many of the gaps in our knowledge about this procedure." Levine is an associate professor in the Section of Surgical Oncology at Wake Forest University School of Medicine, and started the sentinel node mapping program for breast cancer at Wake Forest University Hospital Baptist Medical Center. The program is one of a handful of programs approved in North America for participation in the mapping trial.

The sentinel node may provide valuable information about the status of a woman's cancer without the complications associated with axillary dissection. Preliminary studies suggest that if an analysis shows no cancer cells have spread to the sentinel node, the patient is unlikely to have tumor cells in the remaining axillary nodes. While several studies have examined the validity of the sentinel node procedure, this study is one of the first two randomized trials that will compare the long-term results of sentinel node dissection to full axillary dissection.

A total of 4,000 women across the country will participate in the trial. Patients will be divided into two groups. One group will undergo the current conventional surgery for breast cancer -- either a lumpectomy or mastectomy -- and a sentinel node biopsy followed by an axillary dissection. The second group will also undergo tumor removal and sentinel node biopsy. But if the sentinel node is negative for cancer, women in this group will receive no axillary dissection. If the sentinel node is positive, the other axillary nodes will be removed.

Following standard guidelines for cancer treatment, patients may receive chemotherapy, radiotherapy and/or hormonal therapy following mastectomy. Patients undergoing lumpectomy will also receive breast radiation treatments.

The primary goals of this study are to determine if 1) control of the spread of breast cancer is equivalent between the two procedures, 2) the overall survival and number of years without recurrence are comparable, and 3) the side effects associated with sentinel node removal (lymphedema or swelling caused by excess fluid buildup, a persistent burning sensation, infection and limitation of shoulder movement) are less severe than those from conventional axillary dissection.

Levine adds that the results of thus study will provide essential information about survival, cancer control, and surgical side effects so that patients and doctors can make informed decisions about treatment.

The eligibility criteria for women who want to participate in this trial include having been diagnosed with invasive carcinoma and an operable tumor, but have not yet had definitive surgery.

Physicians or patients interested in more information on the study can call Diane Garski at 336-716-6240.
Media Contact: Jonnie Rohrer, (336) 716-6972, Jim Steele or Mark Wright, (336) 716-4587.

Wake Forest Baptist Medical Center

Related Breast Cancer Articles from Brightsurf:

Oncotarget: IGF2 expression in breast cancer tumors and in breast cancer cells
The Oncotarget authors propose that methylation of DVDMR represents a novel epigenetic biomarker that determines the levels of IGF2 protein expression in breast cancer.

Breast cancer: AI predicts which pre-malignant breast lesions will progress to advanced cancer
New research at Case Western Reserve University in Cleveland, Ohio, could help better determine which patients diagnosed with the pre-malignant breast cancer commonly as stage 0 are likely to progress to invasive breast cancer and therefore might benefit from additional therapy over and above surgery alone.

Partial breast irradiation effective treatment option for low-risk breast cancer
Partial breast irradiation produces similar long-term survival rates and risk for recurrence compared with whole breast irradiation for many women with low-risk, early stage breast cancer, according to new clinical data from a national clinical trial involving researchers from The Ohio State University Comprehensive Cancer Center - Arthur G.

Breast screening linked to 60 per cent lower risk of breast cancer death in first 10 years
Women who take part in breast screening have a significantly greater benefit from treatments than those who are not screened, according to a study of more than 50,000 women.

More clues revealed in link between normal breast changes and invasive breast cancer
A research team, led by investigators from Georgetown Lombardi Comprehensive Cancer Center, details how a natural and dramatic process -- changes in mammary glands to accommodate breastfeeding -- uses a molecular process believed to contribute to survival of pre-malignant breast cells.

Breast tissue tumor suppressor PTEN: A potential Achilles heel for breast cancer cells
A highly collaborative team of researchers at the Medical University of South Carolina and Ohio State University report in Nature Communications that they have identified a novel pathway for connective tissue PTEN in breast cancer cell response to radiotherapy.

Computers equal radiologists in assessing breast density and associated breast cancer risk
Automated breast-density evaluation was just as accurate in predicting women's risk of breast cancer, found and not found by mammography, as subjective evaluation done by radiologists, in a study led by researchers at UC San Francisco and Mayo Clinic.

Blood test can effectively rule out breast cancer, regardless of breast density
A new study published in PLOS ONE demonstrates that Videssa® Breast, a multi-protein biomarker blood test for breast cancer, is unaffected by breast density and can reliably rule out breast cancer in women with both dense and non-dense breast tissue.

Study shows influence of surgeons on likelihood of removal of healthy breast after breast cancer dia
Attending surgeons can have a strong influence on whether a patient undergoes contralateral prophylactic mastectomy after a diagnosis of breast cancer, according to a study published by JAMA Surgery.

Young breast cancer patients undergoing breast conserving surgery see improved prognosis
A new analysis indicates that breast cancer prognoses have improved over time in young women treated with breast conserving surgery.

Read More: Breast Cancer News and Breast Cancer Current Events is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to